Ben PonvilawanNipith CharoenngamThanitsara RittiphairojPatompong UngprasertFaculty of Medicine, Siriraj Hospital, Mahidol UniversityJohns Hopkins Bloomberg School of Public Health2020-05-052020-05-052020-01-01Clinical Lymphoma, Myeloma and Leukemia. (2020)21522669215226502-s2.0-85081952857https://repository.li.mahidol.ac.th/handle/20.500.14594/54484© 2020 Elsevier Inc. Data on receipt of statins and risk of multiple myeloma (MM) are still conflicting. We performed a systematic review that comprised terms for “statin” and “multiple myeloma” and identified 10 eligible studies for meta-analysis. The risk of MM was significantly lower among statin recipients than those who did not receive statins.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicineArticleSCOPUS10.1016/j.clml.2020.02.011